1-苄基氮杂丁烷-3,3-二羧酸二乙酯 | 642411-11-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苄基氮杂丁烷-3,3-二羧酸二乙酯
• 英文名称: diethyl 1-benzylazetidine-3,3-dicarboxylate
• CAS: 642411-11-8
• 化学式: C₁₆H₂₁NO₄
• 分子量: 291.347
• InChiKey: KGNAKGKJEBUHRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Diethyl 1-benzylazetidine-3,3-dicarboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Diethyl 1-benzylazetidine-3,3-dicarboxylate
CAS number: 642411-11-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C16H21NO4
Molecular weight: 291.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-苄基氮杂丁烷-3,3-二羧酸二乙酯 在 palladium(II) hydroxide/carbon 盐酸 、 甲醇 、 lithium aluminium tetrahydride 、 水 、 氢气 、 sodium acetate 、 二正丁基氧化锡 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 24.08h， 生成 1-[(9-deazaadenin-9-yl)methyl]-3-methylthiomethylazetidine-3-methanol hydrochloride
  参考文献：
  名称：

  WO2008/79028

  摘要：

  公开号：
• 作为产物：
  描述：

  双羟甲基丙二酸二乙酯 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 2.67h， 生成 1-苄基氮杂丁烷-3,3-二羧酸二乙酯
  参考文献：
  名称：

  氨与环己胺混合的铂（II）与1-（取代的苄基）氮杂环丁烷-3，3-二羧酸酯的配合物的合成，抗增殖活性和DNA结合研究

  摘要：

  合成和表征了一系列新型的氨/环己胺铂（II）配合物，它们带有1-（取代的苄基）氮杂环丁烷-3，3-二羧酸酯作为离去基团。通过元素分析，IR，1 H NMR和ESI-MS光谱对所有配合物进行表征。已经研究了铂基化合物对几种人类癌细胞系的体外抗增殖活性，表明复合物1和11对顺铂和奥沙利铂对四种细胞系的杀伤力均相当，优于卡铂。药物安全性评估结果（急性毒性研究）显示，复合物11毒性比顺铂和奥沙利铂低得多。流式细胞仪和琼脂糖凝胶电泳研究表明，复合物1和11均诱导肿瘤细胞凋亡，并证明了复合物与pET22b质粒DNA的结合亲和力。

  DOI：

  10.1016/j.ejmech.2011.08.029

文献信息

• [EN] TRPV4 RECEPTOR LIGANDS<br/>[FR] LIGANDS DU RÉCEPTEUR DU TRPV4
  申请人：UNIV UTAH RES FOUND

  公开号：WO2021102314A1

  公开（公告）日：2021-05-27

  Described are receptor ligands of transient receptor potential cation channel subfamily V member 4 (TRPV4), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ocular disorders.

  描述了转瞬性受体电位阳离子通道亚家族V成员4（TRPV4）的受体配体，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗眼部疾病的方法。
• [EN] FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES FUSIONNÉS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：GUO YUNHANG

  公开号：WO2014173289A1

  公开（公告）日：2014-10-30

  The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.

  该发明涉及式(I)的融合杂环化合物及其盐、组合物以及使用方法。具体地，在此披露了某些融合杂环化合物，可用于抑制蛋白激酶，包括布鲁顿酪氨酸激酶（Btk），并用于治疗由此介导的疾病。
• Azetidine Based Transition State Analogue Inhibitors of <i>N</i>-Ribosyl Hydrolases and Phosphorylases
  作者：Gary B. Evans、Richard H. Furneaux、Ben Greatrex、Andrew S. Murkin、Vern L. Schramm、Peter C. Tyler

  DOI：10.1021/jm701265n

  日期：2008.2.1

  ribooxacarbenium carbon from the fixed purine to phosphate and water nucleophiles, respectively. As the lysis reaction progresses along the reaction coordinate, the distance between the purine and carbocation increases and the distance between carbocation and nucleophile decreases. Immucillin-H and DADMe-immucillin-H have been shown previously to be potent inhibitors of purine nucleoside phosphorylases and lie more

  N-核糖基磷酸化酶和水解酶通过将阳离子核糖氧碳carb碳分别从固定的嘌呤迁移到磷酸和水亲核试剂来催化亲核取代反应。随着裂解反应沿着反应坐标进行，嘌呤和碳正离子之间的距离增加，而碳正离子和亲核试剂之间的距离减小。以前已显示Immucillin-H和DADMe-immucillin-H是嘌呤核苷磷酸化酶的有效抑制剂，分别位于该反应坐标的反应物和产物侧。目前正在人类临床试验中针对不同适应症的这两种酶抑制剂都是手性的且制造昂贵。现在，我们报告DADMe-immucillins的氮杂环丁烷类似物的合成，
• Targeting Alzheimer's disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil
  作者：Divan G. van Greunen、Werner Cordier、Margo Nell、Chris van der Westhuyzen、Vanessa Steenkamp、Jenny-Lee Panayides、Darren L. Riley

  DOI：10.1016/j.ejmech.2016.10.036

  日期：2017.2

  A series of twenty seven acetylcholinesterase inhibitors, as potential agents for the treatment of Alzheimer's disease, were designed and synthesised based upon previously unexplored chemical space surrounding the molecular skeleton of the drug donepezil, which is currently used for the management of mild to severe Alzheimer's disease. Two series of analogues were prepared, the first looking at the

  根据之前围绕药物多奈哌齐分子骨架未开发的化学空间，设计和合成了一系列二十七个乙酰胆碱酯酶抑制剂，这些药物可作为治疗阿尔茨海默氏病的潜在药物，目前已用于治疗轻度至重度阿尔茨海默氏病。制备了两个系列的类似物，第一个看待用不同尺寸的饱和含氮环系统取代多奈哌齐中的哌啶环，第二个看待多奈哌齐中茚满酮和哌啶环之间引入不同的连接基。活性最高的类似物5,6-二甲氧基-1-氧代-2,3-二氢-1H-茚满-2-基-1-苄基哌啶-4-羧酸酯（67）的体外IC50值为0.03±0。抗乙酰胆碱酯酶为07μM，未观察到细胞毒性（IC50> 100μM，SH-SY5Y细胞系）。相比之下，多奈哌齐的IC50为0.05±0.06μM，观察到的细胞毒性IC50为15.54±1.12μM。分子建模显示活性和乙酰胆碱酯酶活性位点的计算机内结合之间有很强的相关性。
• [EN] HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES COMME INHIBITEURS DE MK2
  申请人：NOVARTIS AG

  公开号：WO2009010488A1

  公开（公告）日：2009-01-22

  The present invention describes tetracyclic compounds of formula (IA) or (IB), wherein the symbols R, X, A, Y, R2, R3 and D are as defined in the specification, their use in the treatment of certain diseases, e.g. depending on MK-2 or TNF activity, and ways of manufacturing them.

  本发明描述了式（IA）或（IB）的四环化合物，其中符号R、X、A、Y、R2、R3和D如规范中所定义，它们在治疗某些疾病中的用途，例如取决于MK-2或TNF活性，并制造它们的方法。